Literature DB >> 7790319

Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions.

K Shibata1, K Kasahara, T Bando, Y Nakatsumi, M Fujimura, T Tsuruo, T Matsuda.   

Abstract

To elucidate the mechanisms of acquired resistance to mitomycin C (MMC) in non-small cell lung cancer (NSCLC), we established two MMC-resistant NSCLC sublines by continuous exposure to MMC, using PC-9 as a parent cell line. The sublines, PC-9/MC2 and PC-9/MC4, were 6.4- and 10-fold more resistant to MMC than their parent cell line, respectively, at the IC50 value as determined by MTT assay. They exhibited cross-resistance to EO9, but were not resistant to cisplatin, vindesine, etoposide, carboquone, or KW-2149, a novel MMC derivative. They were collaterally sensitive to adriamycin and menadione. Accumulation of the drug was decreased in the resistant sublines to about 60% of that in the parent cells. Cytosolic DT-diaphorase (DTD) activities were decreased to 13.5 +/- 3.2 in PC9/MC2 and 1.3 +/- 0.6 in PC-9/MC4 from 261.5 +/- 92.7 nmol/min/mg protein in the parent PC-9. NADH:cytochrome b5 reductase activities in both of the resistant cell lines were significantly decreased as compared to that in the parent cell line. Addition of dicumarol resulted in a two-fold increase in IC50 value in PC-9, whereas the IC50 value showed no change in PC-9/MC4. Moreover, dicumarol did not affect the sensitivities to KW-2149 but decreased the sensitivities to EO9 in both the parent and the resistant cell lines. Formation of an alkylating metabolite was significantly decreased in the resistant cells, in parallel to the degree of resistance. We concluded that deficient drug activation due to decreased DTD activity was important as a mechanism of resistance to MMC in PC-9, a relatively DTD-rich NSCLC cell line.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790319      PMCID: PMC5920845          DOI: 10.1111/j.1349-7006.1995.tb03079.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


mitomycin C non‐small cell lung cancer DT‐diaphorase calcium‐free and magnesium‐free Dulbecco's phosphate‐buffered saline 3‐[(4‐amino‐2‐methyl‐5‐pyrimidinyl)‐methyl]‐1‐(2‐chloroethyl)‐1‐nitrosourea 3‐hydroxy‐methyl‐5‐aziridinyl‐1‐methyl‐2‐ (H‐indole‐4,7 ‐ indione) propenol dicumarol potassium cyanide dimethyl sulfoxide 3‐[4,5‐dimethylthiazol‐2‐y1]‐2,5‐diphenyltetrazolium bromide glutathione glutathione S‐transferase 4‐(p‐nitrobenzyl)pyridine
  41 in total

1.  DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues.

Authors:  L Dusre; S Rajagopalan; H M Eliot; J M Covey; B K Sinha
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

2.  Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.

Authors:  S R Keyes; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

Review 3.  Bioreductive mechanisms.

Authors:  P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.

Authors:  M I Walton; N Sugget; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Purification and properties of soluble NADH-cytochrome b5 reductase of rabbit erythrocytes.

Authors:  T Yubisui; M Takeshita
Journal:  J Biochem       Date:  1982-05       Impact factor: 3.387

6.  Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.

Authors:  J J Schlager; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia.

Authors:  A Begleiter; E Robotham; M K Leith
Journal:  Mol Pharmacol       Date:  1992-04       Impact factor: 4.436

8.  Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.

Authors:  M Morimoto; T Ashizawa; H Ohno; M Azuma; E Kobayashi; M Okabe; K Gomi; M Kono; Y Saitoh; Y Kanda
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

9.  NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.

Authors:  R D Traver; T Horikoshi; K D Danenberg; T H Stadlbauer; P V Danenberg; D Ross; N W Gibson
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

10.  Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C.

Authors:  M Kono; Y Saitoh; M Kasai; A Sato; K Shirahata; M Morimoto; T Ashizawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-04       Impact factor: 1.645

View more
  3 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

3.  Characterization of a BMS-181174-resistant human bladder cancer cell line.

Authors:  H Xia; R J Bleicher; X Hu; S K Srivastava; V Gupta; H A Zaren; S V Singh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.